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Evidence That Lower Is Better?Ori Ben-Yehuda, MD,y Anthony N. DeMaria, MDzA pproximately 25 years ago, the ﬁrst AdultTreatment Panel (ATP) guidelines set thestage for low-density lipoprotein cholesterol
(LDL-C) as both a risk factor and a target of therapy
(1). Since then, ever-accumulating evidence on the
role of LDL-C in atherosclerosis, coupled with the
availability of more potent statins and data that
“lower is better,” have led to what appears to be an
inexorable march toward lower LDL-C goals, particu-
larly for secondary prevention. ATP-III (2), published
in 2001, deﬁned the optimal LDL level as <100 mg/dl,
to be followed in an update in 2004, which estab-
lished a goal of <70 mg/dl as an option in very high-
risk patients (3).
In November 2013, the American College of Cardi-
ology (ACC) and the American Heart Association
(AHA) published a much-anticipated guideline up-
date, in which the most surprising and controversial
change was the abandonment of LDL-C targets and
dose titration (4). Instead, either moderate- or high-
intensity statin therapy was recommended on the
basis of underlying risk categories, irrespective of
LDL-C response. Measurement of on-therapy LDL-C
was recommended only for the purpose of assessing
adherence. Notably, the American Association of
Clinical Endocrinology (5) as well as the National
Lipid Association (6) refused to endorse the new
recommendations.SEE PAGE 485
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report a patient-level meta-analysis of data from
large statin trials, which informs the discussion
surrounding the 2013 ACC/AHA guidelines. The
authors provide important information on the vari-
ability of lipoprotein levels achieved with treatment,
as well as the cardiovascular risk reduction associated
with different lipoprotein levels attained. The key
question they address is whether there is evidence
that patients who achieve lower LDL levels, <100
mg/dl, <70 mg/dl, or even <50 mg/dl, have a
reduced cardiovascular risk. With this objective, they
analyzed individual patient data (provided by the
investigators) from 8 large-scale randomized trials.
The authors found that more than 40% of the
participants in these trials did not reach an LDL-C
level <70 mg/dl despite being prescribed high-dose
statin therapy, deﬁned as rosuvastatin 20 mg or
atorvastatin 80 mg. Findings were similar when
the data were analyzed for apolipoprotein B and for
non–high-density lipoprotein cholesterol, 2 measure-
ments thatmay be better than LDL-C as risk predictors,
but which are not as familiar to the general public (8).
In terms of risk reduction, there was a clear rela-
tionship between LDL-C level attained and cardio-
vascular risk, with the major cardiovascular event rate
at 1 year increasing incrementally from 4.4% in those
with LDL-C levels <50 mg/dl, to 10.9% for LDL-C
between 50 and <70 mg/dl, 16% between 70 and
<100mg/dl, and up to 34.4% in those with LDL-C$190
mg/dl. This relationship supports the premise that
“lower is better” when it comes to LDL-C goals.
An important limitation of the large statin trials
conducted to date—and therefore by extension this
meta-analysis by Boekholdt et al. (7)—is that these
trials (with the exception of the limited dose titration
in 4S [Scandinavian Simvastatin Survival Study] [9]
and AFCAPS/TexCAPS [Air Force/Texas Coronary
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496Atherosclerosis Prevention Study] [10]) examined
ﬁxed doses of statins. The different LDL-C levels
attained were therefore not due to a strategy of
individualized goal attainment, which would have
involved dose titration and possibly the addition of
other agents, such as ezetimibe or nicotinic acid, but
due to the complex interaction between the statin
(including the dose) and the individual patient’s
biology. Indeed, only a small number of subjects in
each trial achieved an LDL-C level of <50 mg/dl (11%
in the pooled population). These patients are
different from those with a less robust response;
hence, it remains unclear whether it is the LDL-C
level achieved or the patient’s ability to respond to
a statin dose that is the key determinant of the better
outcomes.
Several important questions remain. Is it acceptable
if a patient reaches a desired LDL-C level at a less-than-
moderate or high-intensity statin dose, or is there an
additional beneﬁt to receiving a higher dose of a statin?
Also uncertain is whether a statin sparing combination
therapy would be as efﬁcacious as high-intensity
agents. Although data from statin trials such as the
JUPITER (Justiﬁcation for the Use of Statins in Pre-
vention: an Intervention Trial Evaluating Rosuvasta-
tin) study (11) suggest that adverse events in patients
achieving LDL-C levels<50mg/dl are no different from
in thosewho do not, an increased incidence of diabetes
exists. In addition, there are undoubtedly patients
who cannot tolerate the highest statin doses.
There are many factors that may affect LDL-C
reduction and achieved LDL-C levels. Patient
compliance and starting LDL-C levels are the most
obvious and probably most important. But underlying
biology also plays a role. A relatively small population
of patients, termed “hyper-responders,” can be
identiﬁed who achieve low LDL-C levels (typically on
relatively low doses of statins) and have very low
event rates. However, the mechanisms driving hyper-
responsiveness are poorly understood. Factors
favoring greater LDL-C reduction that were identiﬁed
in a pooled analysis of data from more than 21,000
patients included the presence of diabetes mellitus,
black race, and male sex, but these factors had only
a modest overall effect (12). Particularly intriguing
is the possible role of the PCSK9 gene, with loss of
function associated with an increased response tostatins (13), but the genetic response to statins is
likely polygenetic and is still poorly understood.
Beyond the LDL-C level attained, cardiovascular
risk reduction may also vary by underlying disease
and metabolic state. In an analysis of data from the
4S study, it was shown that patients with low
HDL-C cholesterol and elevated triglycerides along
with elevated LDL-C (lipid triad) beneﬁted much
more from simvastatin use than did patients with
isolated elevated LDL-C, who had only marginal
beneﬁt (14).
The strengths of the meta-analysis by Boekholdt
et al. (7) include the patient-level analysis and
the large number of patients. The main limitation,
beyond the post-hoc observational nature of the
data and the different inclusion criteria, which
the authors acknowledged, is that the LDL-C
levels attained may have been inﬂuenced by a
myriad of factors, which in themselves may affect
cardiovascular risk. In this regard, the present meta-
analysis does not disprove the 2013 ACC/AHA guide-
lines contention (4) that there are inadequate data
at the present time to indicate speciﬁc LDL-C
targets of therapy. Unfortunately, even the much-
anticipated IMPROVE-IT (Improved Reduction of
Outcomes: Vytorin Efﬁcacy International Trial),
which is randomizing patients to simvastatin alone
versus simvastatin/ezetimibe therapy, is unlikely to
be deﬁnitive in this regard, as it too is largely ﬁxed-
dose based, with the only response related titration
being the increase in simvastatin dose from 40 to
80 mg in those with LDL-C >79 mg/dl (15). It has
been estimated that with the current ACC/AHA
guidelines, 56 million U.S. patients are eligible for
statin therapy (16). It is indeed regrettable that more
than 25 years after the ﬁrst ATP guidelines, we still
do not have clear-cut evidence on what the appro-
priate LDL-C targets of therapy should be. The ﬁnd-
ings from the present meta-analysis will hopefully
further spur the design and implementation of lipid
trials assessing speciﬁc LDL-C targets rather than
speciﬁc drug doses.
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